A new blood test may extend the window of accurate detection from weeks to months after the onset of Zika infection, giving clinicians a powerful new tool to screen for Zika throughout pregnancy, a new study led by an Indian-orgin researcher suggests.
Infection with Zika virus during pregnancy raises risk for neurodevelopmental problems in the offspring, including fetal microcephaly -- a condition in which a baby's head is significantly smaller than expected -- in at least one in ten pregnancies.
The blood test called ZIKV-NS2B-concat ELISA improves on existing options, providing an accurate and cost-effective means to determine whether a patient was infected, days or months after exposure, the researcher said.
"Many people infected by Zika have only mild illness, or are unable to see a clinician in the early, acute phase of infection. Our new test greatly extends the window during which an individual can be assessed with accuracy," said Nischay Mishra from the Center for Infection and Immunity (CII) at Columbia University.
The blood test quickly detects up to 200 samples in four hours and the researchers anticipate its cost will be similar to other ELISA tests used in clinical settings, the researcher said.
"An affordable and accurate test for Zika virus is critical for public health," said W. Ian Lipkin, co-author of the study published in the journal mBio.
To develop and evaluate the test, the researchers analysed blood samples collected from children in the Nicaraguan Pediatric Dengue Cohort Study, all of whom had previously tested positive for Zika virus.
Using a microarray, they identified a unique peptide sequence -- a short section of amino acids -- that binds with antibodies to Zika virus but not with antibodies to similar viruses like dengue, yellow fever, and Japanese encephalitis.
Next, the researchers customised a low-cost testing technology called enzyme-linked immunosorbent assay (ELISA) to work with the sequence-improving on current versions of the ELISA test which use larger sections proteins that bind to the virus.
--IANS
vc/qd/dg
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
